Combination therapy of p53 siRNA and epigallocatechin-3-gallate (EGCG) reduced the stimulation of anti-apoptotic genes related to therapy resistance, such as BAG3, XIAP, and RIPK2, which may enhance the sensitivity of cancer cells to therapy in TNBC tumors. Here, TP53 is linked to cancer.